News

Zacks Investment Research on MSN1d
Lilly Down 17% Since Q1 Results: Should You Buy the Dip in LLY Stock?
Eli Lilly and Company’s LLY shares have lost 17% so far in May. Lilly announced mixed earnings results on May 1. It missed ...
Patients Are Left With Few Options as GLP-1 Copycats Disappear
With the active ingredients in drugs like Ozempic and Zepbound no longer in shortage, access to medicine for millions who had ...
Eli Lilly downplays CVS move to drop Zepbound coverage, shares plunge
Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...
Eli Lilly Stock Offers Buying Opportunity For Goldman Sachs. Concerns Over CVS Setback Are Overblown, Analysts Say
Eli Lilly's Zepbound loses CVS coverage to Wegovy, prompting analyst debate on pricing pressures and long-term obesity market ...
Beyond Valuation Ratios: 3 Undervalued Stocks To Buy In May 2025
Looking for undervalued stocks? Check out three top undervalued stocks to buy now in May, 2025 to boost your portfolio.
Why Patients Are Being Forced to Switch to a 2nd-Choice Obesity Drug
CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...